Akeso Inc (9926.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG0146B1032
Akeso Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.12 bn CNY | 3.16 bn CNY |
| Gross profit | 1.64 bn CNY | 2.48 bn CNY |
| EBIT | -508.70 m CNY | -973.09 m CNY |
| Net income | -514.52 m CNY | -1.15 bn CNY |
| Diluted EPS – continuing operations | -0.54 CNY | -1.26 CNY |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Akeso Inc
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
More stocks
- FactSet (FDS)
- Kikkoman Corp (2801.T)
- Shizuoka Financial Group Inc (5831.T)
- Inner Mongolia Yitai Coal Co Ltd (900948.SS)
- Suzano Papel e Celulose SA ADR (SUZ)
- Tsingtao Brewery Co Ltd (600600.SS)
- J Sainsbury PLC (SBRY.L)
- Discovery Ltd (DSY.JO)
- Subsea 7 SA (SUBC.OL)
- Hensoldt (HAG.DE)
- ImmunityBio, Inc. (IBRX)
- Quebecor Inc (QBR.B.TO)
Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.